Form 6-K ASTRAZENECA PLC For: Aug 11
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of August
2022
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F
__
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes
__ No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
Acquisition of TeneoTwo completed
11 August 2022 07:00 BST
Acquisition of TeneoTwo for its clinical-stage
T-cell engager completed
AstraZeneca has completed the acquisition of
TeneoTwo, Inc.
(TeneoTwo)i,
including its Phase I clinical-stage CD19/CD3 T-cell engager,
TNB-486, currently under evaluation in relapsed and refractory
B-cell non-Hodgkin lymphoma.1 AstraZeneca
will develop TNB-486 as a potential new medicine for B-cell
haematologic malignancies.
Financial considerations
AstraZeneca has acquired all outstanding equity of TeneoTwo in
exchange for an upfront payment of $100m. Under
the terms of the agreement, AstraZeneca will make additional
contingent R&D-related milestone payments of up to $805m and
additional contingent commercial-related milestone payments of up
to $360m to TeneoTwo's former equity
holders.
This acquisition did not include the transfer of people or
facilities.
iTeneoTwo, Inc., is a majority
owned subsidiary company of TBio, LLC, a limited liability company
formed in Delaware, US
Notes
AstraZeneca in haematology
AstraZeneca is pushing the boundaries of science to redefine care
in haematology. We have expanded our commitment to patients with
haematologic conditions, not only in oncology but also in rare
diseases with the acquisition of Alexion, allowing us to reach more
patients with high unmet needs. By applying our deep understanding
of blood cancers, leveraging our strength in solid tumour oncology
and delivering on Alexion's pioneering legacy in complement science
to provide transformative medicines for rare diseases, we are
pursuing the end-to-end development of novel therapies designed to
target underlying drivers of disease.
By targeting haematological conditions with high unmet medical
needs, we aim to deliver innovative medicines and approaches to
improve patient outcomes. Our goal is to help transform the lives
of patients living with malignant, rare and other related
haematologic diseases, shaped by insights from patients, caregivers
and physicians to have the most meaningful impact.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition
to provide cures for cancer in every form, following the science to
understand cancer and all its complexities to discover, develop and
deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It
is through persistent innovation that AstraZeneca has built one of
the most diverse portfolios and pipelines in the industry, with the
potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1. Clinicaltrials.gov. A Study of
TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin
Lymphoma. Available at https://clinicaltrials.gov/ct2/show/NCT04594642.
Accessed 2 August 2022.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
AstraZeneca
PLC
|
Date:
11 August
2022
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
- Breakdown of debtors, Realkredit Danmark A/S
- Net Asset Value(s)
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!